{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T10:56:04Z","timestamp":1775559364033,"version":"3.50.1"},"reference-count":190,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genome Ed."],"abstract":"<jats:p>\n                    In recent years gene therapy has emerged as a powerful technology for treatment of a large variety of inherited disorders. With the FDA approval of\n                    <jats:italic>in vivo<\/jats:italic>\n                    gene therapy of hemophilia A and B using AAV-mediated transgene delivery to hepatocytes, the path towards a new treatment era seemed paved. Also, CRISPR-Cas based approaches have reached the clinic, as in the\n                    <jats:italic>ex vivo<\/jats:italic>\n                    treatment of hematopoietic stem cells for sickle cell disease and thalassemia patients. The question arises whether these innovative strategies will also be suitable for patients with von Willebrand Disease (VWD). Whilst\n                    <jats:italic>in<\/jats:italic>\n                    and\n                    <jats:italic>ex vivo<\/jats:italic>\n                    delivery to endothelial cells (ECs) has been demonstrated, and CRISPR-Cas9 gene editing has been successful in ECs, there are currently no gene therapy options available for VWD. The wide variety of pathogenic VWF mutations makes development of broadly applicable, cost-effective gene therapies challenging. While delivery of von Willebrand factor (VWF) as a therapeutic transgene would be optimal, the size of VWF challenges efficient delivery. Therefore, treatment of VWD requires targeted, personalized gene therapy; for instance by using the newest CRISPR-Cas technologies which can be tailored to facilitate alteration and restoration of various pathogenic VWD variants. This review describes the inherited bleeding disorder VWD and potential gene therapy approaches for management of the disease. Thereby we are exploring different CRISPR-Cas technologies and recent developments in the field. Moreover, we will discuss the ongoing advances of\n                    <jats:italic>in vivo<\/jats:italic>\n                    delivery systems, all with the scope on ECs.\n                  <\/jats:p>","DOI":"10.3389\/fgeed.2025.1620438","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:30:06Z","timestamp":1758519006000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Rewriting the script: gene therapy and genome editing for von Willebrand Disease"],"prefix":"10.3389","volume":"7","author":[{"given":"Alastair","family":"Barraclough","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"B\u00e4r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tirsa","family":"van Duijl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Fijnvandraat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen C. J.","family":"Eikenboom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank W. G.","family":"Leebeek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Bierings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Voorberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Despoina","family":"Trasanidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100394","DOI":"10.1016\/J.XPRO.2021.100394","article-title":"Differentiation and characterization of human IPSC-derived vascular endothelial cells under physiological shear stress","volume":"2","author":"Abutaleb","year":"2021","journal-title":"Star. Protoc."},{"key":"B2","doi-asserted-by":"publisher","first-page":"20959","DOI":"10.1073\/PNAS.1818461116","article-title":"Francisella novicida Cas9 interrogates genomic DNA with very high specificity and can be used for mammalian genome editing","volume":"116","author":"Acharya","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1101\/gr.255414.119","article-title":"Versatile and robust genome editing with Streptococcus thermophilus CRISPR1-Cas9","volume":"30","author":"Agudelo","year":"2020","journal-title":"Genome Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"103181","DOI":"10.1016\/J.DNAREP.2021.103181","article-title":"The dark side of homology-directed repair","volume":"106","author":"Al-Zain","year":"2021","journal-title":"DNA Repair"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1634\/THEONCOLOGIST.2019-0233","article-title":"The european medicines agency review of kymriah (tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large b\u2010cell lymphoma","volume":"25","author":"Ali","year":"2019","journal-title":"Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/s41587-023-02078-y","article-title":"Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo","volume":"42","author":"An","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-Replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"E718","DOI":"10.1097\/HS9.0000000000000718","article-title":"Importance of Genotyping in von Willebrand Disease to Elucidate Pathogenic Mechanisms and Variability in Phenotype","volume":"6","author":"Atiq","year":"2022","journal-title":"HemaSphere"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1182\/BLOOD.2023022457","article-title":"Type 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies","volume":"143","author":"Atiq","year":"2023","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","article-title":"Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins","volume":"185","author":"Banskota","year":"2022","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"102503","DOI":"10.1016\/j.rpth.2024.102503","article-title":"Oral communication abstracts","volume":"8","author":"B\u00e4r","year":"2024","journal-title":"Res. Pract. Thrombosis Haemostasis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/J.JTHA.2024.10.023","article-title":"The Severe von Willebrand Disease Variant p.M771V Leads to Impaired Anterograde Trafficking of von Willebrand Factor in Patient-Derived and Base-Edited Endothelial Colony-Forming Cells","volume":"23","author":"B\u00e4r","year":"2025","journal-title":"J. Thrombosis Haemostasis JTH"},{"key":"B13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41434-020-00218-6","article-title":"Development of a Dual Hybrid AAV Vector for Endothelial-Targeted Expression of von Willebrand Factor","volume":"30","author":"Barbon","year":"2021","journal-title":"Gene Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1038\/S41598-022-07158-8","article-title":"Transposase-CRISPR mediated targeted integration (TransCRISTI) in the human genome","volume":"12","author":"Bazaz","year":"2022","journal-title":"Sci. Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.1182\/BLOOD-2010-09-306761","article-title":"Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection","volume":"117","author":"Biffi","year":"2011","journal-title":"Blood"},{"key":"B188","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s40265-022-01788-y","article-title":"Valoctocogene roxaparvovec: first approval","volume":"82","author":"Blair","year":"2022","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/J.YMTHE.2020.12.010","article-title":"Genome editing in human hematopoietic stem and progenitor cells via CRISPR-Cas9-Mediated homology-independent targeted integration","volume":"29","author":"Bloomer","year":"2020","journal-title":"Mol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1182\/BLOOD.V120.21.1076.1076","article-title":"Comparative cellular studies of the VWF exon 4\u20135 deletion mutation using patient-derived blood outgrowth endothelial cells (BOEC) and megakaryocytes","volume":"120","author":"Bowman","year":"2012","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1021\/acsnano.7b06995","article-title":"Directing nanoparticle biodistribution through evasion and exploitation of Stab2-Dependent nanoparticle uptake","volume":"12","author":"Campbell","year":"2018","journal-title":"ACS Nano"},{"key":"B19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/JTH.15131","article-title":"In vivo Modulation of a Dominant\u2010negative Variant in Mouse Models of von Willebrand Disease Type 2A","volume":"19","author":"Campioni","year":"2021","journal-title":"J. Thrombosis Haemostasis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"277ra28","DOI":"10.1126\/scitranslmed.aaa1405","article-title":"Liver-directed lentiviral gene therapy in a dog model of hemophilia B","volume":"7","author":"Cantore","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/J.YMTHE.2023.01.021","article-title":"Extracellular vesicles: the next generation in gene therapy delivery","volume":"31","author":"Cecchin","year":"2023","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/J.MOLCEL.2012.07.029","article-title":"Playing the end game: DNA double-strand break repair pathway choice","volume":"47","author":"Chapman","year":"2012","journal-title":"Mol. Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"eaau0766","DOI":"10.1126\/SCIADV.AAU0766","article-title":"Minimal PAM specificity of a highly similar SpCas9 ortholog","volume":"4","author":"Chatterjee","year":"2018","journal-title":"Sci. Adv."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41587-024-02437-3","article-title":"Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR\u2013Cas9 ribonucleoprotein","volume":"2024","author":"Chen","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/s41467-021-21559-9","article-title":"Programmable C:G to G:C genome editing with CRISPR-Cas9-Directed base excision repair proteins","volume":"12","author":"Chen","year":"2021","journal-title":"Nat. Commun."},{"key":"B26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41589-022-01163-8","article-title":"Engineering a precise adenine base editor with minimal bystander editing","volume":"19","author":"Chen","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1016\/J.CELL.2021.09.018","article-title":"Enhanced prime editing systems by manipulating cellular determinants of editing outcomes","volume":"184","author":"Chen","year":"2021","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/J.JGG.2022.06.001","article-title":"Long-term correction of hemophilia B through CRISPR\/Cas9 induced homology-independent targeted integration","volume":"49","author":"Chen","year":"2022","journal-title":"J. Genet. Genomics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1\u20132 trial of AAVS3 gene therapy in patients with hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/jth.15713","article-title":"Molecular pathogenesis and heterogeneity in type 3 VWD families in U.S. zimmerman program","volume":"20","author":"Christopherson","year":"2022","journal-title":"J. Thrombosis Haemostasis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/J.JTHA.2023.11.016","article-title":"The common VWF variant p.Y1584C: detailed pathogenic examination of an enigmatic sequence change","volume":"22","author":"Christopherson","year":"2024","journal-title":"J. Thrombosis Haemostasis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1056\/NEJMoa2405734","article-title":"CRISPR-based therapy for hereditary angioedema","volume":"392","author":"Cohn","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/BLOODADVANCES.2020003264","article-title":"ASH ISTH NHF WFH 2021 Guidelines on the Management of von Willebrand Disease","volume":"5","author":"Connell","year":"2021","journal-title":"Blood Adv."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3390\/pharmaceutics13081217","article-title":"Improved functionality of integration-deficient lentiviral vectors (IDLVs) by the inclusion of IS2 protein docks","volume":"13","author":"Cortijo-Guti\u00e9rrez","year":"2021","journal-title":"Pharmaceutics"},{"key":"B35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/NM.3793","article-title":"Therapeutic genome editing: prospects and challenges","volume":"21","author":"Cox","year":"2015","journal-title":"Nat. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41587-024-02488-6","article-title":"Genome editing with the HDR-enhancing DNA-PKcs inhibitor AZD7648 causes large-scale genomic alterations","volume":"2024","author":"Cullot","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1016\/J.JTHA.2024.06.020","article-title":"Type 2N von Willebrand Disease: Genotype Drives Different Bleeding Phenotypes and Treatment Needs","volume":"22","author":"Daniel","year":"2024","journal-title":"J. Thrombosis Haemostasis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/s41551-022-00911-4","article-title":"Efficient in vivo base editing via single adeno-Associated viruses with size-optimized genomes encoding compact adenine base editors","volume":"6","author":"Davis","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e0297465","DOI":"10.1371\/JOURNAL.PONE.0297465","article-title":"Approaches to induce the maturation process of human induced pluripotent stem cell derived-endothelial cells to generate a robust model","volume":"19","author":"de Boer","year":"2024","journal-title":"PLOS ONE"},{"key":"B40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/J.THROMRES.2017.09.025","article-title":"Von Willebrand Disease Mutation Spectrum and Associated Mutation Mechanisms","volume":"159","author":"de Jong","year":"2017","journal-title":"Thrombosis Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1055\/S-0040-1715442","article-title":"Ex Vivo Improvement of a von Willebrand Disease Type 2A Phenotype Using an Allele-Specific Small-Interfering RNA","volume":"120","author":"De Jong","year":"2020","journal-title":"Thrombosis Haemostasis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1073\/pnas.1219885110","article-title":"Linkage Analysis Identifies a Locus for Plasma von Willebrand Factor Undetected by Genome-Wide Association","volume":"110","author":"Desch","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0247603","DOI":"10.1371\/JOURNAL.PONE.0247603","article-title":"Systematic analysis of factors that improve Homologous direct repair (HDR) efficiency in CRISPR\/Cas9 technique","volume":"16","author":"Di Stazio","year":"2021","journal-title":"PLOS ONE"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa2405541","article-title":"Hematologic cancer after gene therapy for cerebral adrenoleukodystrophy","volume":"391","author":"Duncan","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1038\/s41598-023-29789-1","article-title":"CRISPR\/Cas9-Mediated targeted Knock-in of large constructs using nocodazole and RNase HII","volume":"13","author":"Eghbalsaied","year":"2023","journal-title":"Sci. Rep. 2023"},{"key":"B46","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1053\/BEHA.2001.0139","article-title":"Congenital von Willebrand Disease Type 3: clinical Manifestations, Pathophysiology and Molecular Biology","volume":"14","author":"Eikenboom","year":"2001","journal-title":"Best Pract. and Res. Clin. Haematol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"12297","DOI":"10.1093\/NAR\/GKAA998","article-title":"PpCas9 from pasteurella pneumotropica - a compact type II-C Cas9 ortholog active in human cells","volume":"48","author":"Fedorova","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1038\/s41596-024-01090-z","article-title":"Precise kilobase-scale genomic insertions in mammalian cells using PASTE","volume":"20","author":"Fell","year":"2024","journal-title":"Nat. Protoc."},{"key":"B49","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41587-023-01915-4","article-title":"Genotoxic effects of base and prime editing in human hematopoietic stem cells","volume":"42","author":"Fiumara","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"306","DOI":"10.2174\/156652307782151515","article-title":"Immune responses to lentiviral vectors","volume":"7","author":"Follenzi","year":"2007","journal-title":"Curr. Gene Ther."},{"key":"B51","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.1111\/FEBS.16808","article-title":"Gene Silencing of Endothelial von Willebrand Factor Reduces the Susceptibility of Human Endothelial Cells to SARS-CoV-2 Infection","volume":"290","author":"Furini","year":"2023","journal-title":"FEBS J."},{"key":"B52","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u02d9T to G\u02d9C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1182\/BLOOD-2007-12-130740","article-title":"Basal Secretion of von Willebrand Factor from Human Endothelial Cells","volume":"112","author":"Giblin","year":"2008","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/BLOOD-2015-02-629873","article-title":"Hemostatic Efficacy, Safety, and Pharmacokinetics of a Recombinant von Willebrand Factor in Severe von Willebrand Disease","volume":"126","author":"Gill","year":"2015","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/nejmoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B57","unstructured":"gnomAD.boradinstitte\n          \n          \n          2025"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1123805","DOI":"10.3389\/FIMMU.2023.1123805","article-title":"Platforms, advances, and technical challenges in virus-like particles-based vaccines","volume":"14","author":"Gupta","year":"2023","journal-title":"Front. Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","article-title":"CRISPR\u2013Cas9 genome editing induces a P53-Mediated DNA damage response","volume":"24","author":"Haapaniemi","year":"2018","journal-title":"Nat. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1182\/BLOOD-2015-04-512731","article-title":"Von Willebrand Factor Propeptide: biology and Clinical Utility","volume":"126","author":"Haberichter","year":"2015","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s13287-022-02924-x","article-title":"High-efficient serum-free differentiation of endothelial cells from human IPS cells","volume":"13","author":"Hamad","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41467-017-01408-4","article-title":"A thermostable Cas9 with increased lifetime in human plasma","volume":"8","author":"Harrington","year":"2017","journal-title":"Nat. Commun."},{"key":"B189","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40265-023-01845-0","article-title":"Etranacogene dezaparvovec: first approval","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"key":"B63","first-page":"1","article-title":"First-pass effect","volume-title":"XPharm: the comprehensive pharmacology reference","author":"Herman","year":"2023"},{"key":"B64","unstructured":"HGMD\u00ae home page\n          \n          \n          2025"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/J.JTHA.2024.01.015","article-title":"A New Look at an Old Body: molecular Determinants of Weibel-Palade Body Composition and von Willebrand Factor Exocytosis","volume":"22","author":"Hordijk","year":"2024","journal-title":"J. Thrombosis Haemostasis JTH"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e3000686","DOI":"10.1371\/JOURNAL.PBIO.3000686","article-title":"A compact Cas9 ortholog from Staphylococcus auricularis (SauriCas9) expands the DNA targeting scope","volume":"18","author":"Hu","year":"2020","journal-title":"PLoS Biol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41556-023-01342-2","article-title":"C-to-G editing generates double-strand breaks causing deletion, transversion and translocation","volume":"26","author":"Huang","year":"2024","journal-title":"Nat. Cell Biol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/J.JARE.2024.07.006","article-title":"Exploitation of enhanced prime editing for blocking aberrant angiogenesis","volume":"72","author":"Huang","year":"2024","journal-title":"J. Adv. Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41591-018-0050-6","article-title":"P53 inhibits CRISPR\u2013Cas9 engineering in human pluripotent stem cells","volume":"24","author":"Ihry","year":"2018","journal-title":"Nat. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1182\/BLOOD-2011-06-360875","article-title":"Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage","volume":"119","author":"Jacobi","year":"2012","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/J.1538-7836.2006.01860.X","article-title":"Genetic Linkage and Association Analysis in Type 1 von Willebrand Disease: results from the Canadian Type 1 VWD Study","volume":"4","author":"James","year":"2006","journal-title":"J. Thrombosis Haemostasis JTH"},{"key":"B72","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1182\/BLOODADVANCES.2020003265","article-title":"ASH ISTH NHF WFH 2021 Guidelines on the Diagnosis of von Willebrand Disease","volume":"5","author":"James","year":"2021","journal-title":"Blood Adv."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3390\/v14102087","article-title":"Baculovirus-free SARS-CoV-2 virus-like particle production in insect cells for rapid neutralization assessment","volume":"14","author":"Jaron","year":"2022","journal-title":"Viruses"},{"key":"B74","doi-asserted-by":"publisher","first-page":"695937","DOI":"10.3389\/FNMOL.2021.695937","article-title":"Current and future prospects for gene therapy for rare genetic diseases affecting the brain and spinal cord","volume":"14","author":"Jensen","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable Dual-RNA-Guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"B76","doi-asserted-by":"publisher","first-page":"6108","DOI":"10.1182\/BLOODADVANCES.2023010643","article-title":"Small Interfering RNA\u2013Mediated Allele-Selective Silencing of von Willebrand Factor in vitro and in vivo","volume":"7","author":"Jongejan","year":"2023","journal-title":"Blood Adv."},{"key":"B77","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/J.THROMRES.2024.03.002","article-title":"Impact of Allele-Selective Silencing of von Willebrand Factor in Mice Based on a Single Nucleotide Allelic Difference in von Willebrand Factor","volume":"236","author":"Jongejan","year":"2024","journal-title":"Thrombosis Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.7150\/THNO.77259","article-title":"Lipid nanoparticles for delivery of RNA therapeutics: current status and the role of in vivo imaging","volume":"12","author":"Jung","year":"2022","journal-title":"Theranostics"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1161\/ATVBAHA.120.314245","article-title":"Orchestration of primary hemostasis by platelet and endothelial lysosome-related organelles","volume":"40","author":"Karampini","year":"2020","journal-title":"Arteriosclerosis, Thrombosis, Vasc. Biol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1172\/JCI9516","article-title":"Vasopressin-Induced von Willebrand Factor Secretion from Endothelial Cells Involves V2 Receptors and CAMP","volume":"106","author":"Kaufmann","year":"2000","journal-title":"J. Clin. Investigation"},{"key":"B81","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/S40291-021-00555-1","article-title":"Elivaldogene autotemcel: first approval","volume":"25","author":"Keam","year":"2021","journal-title":"Mol. Diagnosis and Ther."},{"key":"B82","doi-asserted-by":"publisher","first-page":"eabf4398","DOI":"10.1126\/SCIADV.ABF4398","article-title":"Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver","volume":"7","author":"Kim","year":"2021","journal-title":"Sci. Adv."},{"key":"B83","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR\u2013Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41587-020-0609-x","article-title":"CRISPR C-to-G base editors for inducing targeted DNA transversions in human cells","volume":"39","author":"Kurt","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1016\/J.JTHA.2024.08.011","article-title":"Endothelial Colony-Forming Cells in the Spotlight: insights into the Pathophysiology of von Willebrand Disease and Rare Bleeding Disorders","volume":"22","author":"Laan","year":"2024","journal-title":"J. Thrombosis Haemostasis JTH"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1182\/BLOOD.2024026804","article-title":"DDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysis","volume":"145","author":"Laan","year":"2025","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/bjh.13064","article-title":"The Diagnosis and Management of von Willebrand Disease: a United Kingdom Haemophilia Centre Doctors Organization Guideline Approved by the British Committee for Standards in Haematology","volume":"167","author":"Laffan","year":"2014","journal-title":"Br. J. Haematol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41587-022-01611-9","article-title":"Improved cytosine base editors generated from TadA variants","volume":"41","author":"Lam","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/MT.2016.8","article-title":"The Neisseria meningitidis CRISPR-Cas9 System enables specific genome editing in mammalian cells","volume":"24","author":"Lee","year":"2016","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1056\/NEJMRA1601561","article-title":"Von Willebrand\u2019s Disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1182\/BLOOD.2021014810","article-title":"Recombinant von Willebrand Factor Prophylaxis in Patients with Severe von Willebrand Disease: phase 3 Study Results","volume":"140","author":"Leebeek","year":"2022","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1182\/BLOOD-2014-06-528406","article-title":"Von Willebrand Factor Biosynthesis, Secretion, and Clearance: connecting the Far Ends","volume":"125","author":"Lenting","year":"2015","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1182\/BLOOD.2023023277","article-title":"How Unique Structural Adaptations Support and Coordinate the Complex Function of von Willebrand Factor","volume":"144","author":"Lenting","year":"2024","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1126\/science.1068893","article-title":"Murine leukemia induced by retroviral gene marking","volume":"296","author":"Li","year":"2002","journal-title":"Science"},{"key":"B95","doi-asserted-by":"publisher","first-page":"102344","DOI":"10.1016\/j.omtn.2024.102344","article-title":"CRISPR-Cas9-Mediated homology-directed repair for precise gene editing","volume":"35","author":"Liao","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B96","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1182\/BLOODADVANCES.2024014601","article-title":"Amelioration of a von Willebrand Disease Type 2B Phenotype in vivo upon Treatment with Allele-Selective SiRNAs","volume":"9","author":"Linthorst","year":"2024","journal-title":"Blood Adv."},{"key":"B97","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/17474086.2025.2459259","article-title":"The Future of SiRNA-Mediated Approaches to Treat von Willebrand Disease","volume":"18","author":"Linthorst","year":"2025","journal-title":"Expert Rev. Hematol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"5320","DOI":"10.1128\/jvi.74.11.5320-5328.2000","article-title":"Incorporation of tumor vasculature targeting motifs into moloney murine leukemia Virus env escort proteins enhances retrovirus binding and transduction of human endothelial cells","volume":"74","author":"Liu","year":"2000","journal-title":"J. Virology"},{"key":"B99","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41586-019-0908-x","article-title":"CasX enzymes comprise a distinct family of RNA-Guided genome editors","volume":"566","author":"Liu","year":"2019","journal-title":"Nat. 2019"},{"key":"B100","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/labinvest.2014.78","article-title":"The myeloid-binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting","volume":"94","author":"Lu","year":"2014","journal-title":"Lab. Investig."},{"key":"B101","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1093\/NAR\/GKZ605","article-title":"Delivering Cas9\/SgRNA ribonucleoprotein (RNP) by lentiviral capsid-based bionanoparticles for efficient \u2018Hit-and-Run\u2019 genome editing","volume":"47","author":"Lyu","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B102","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1089\/CRISPR.2024.0019","article-title":"Prime editing of vascular endothelial growth factor receptor 2 attenuates angiogenesis in vitro","volume":"7","author":"Ma","year":"2024","journal-title":"arXiv"},{"key":"B103","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/JTH.15586","article-title":"Von Willebrand Disease Type 2M: correlation between Genotype and Phenotype","volume":"20","author":"Maas","year":"2021","journal-title":"J. Thrombosis Haemostasis"},{"key":"B104","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41467-018-07845-z","article-title":"Genome editing in primary cells and in vivo using viral-derived nanoblades loaded with Cas9-SgRNA ribonucleoproteins","volume":"10","author":"Mangeot","year":"2019","journal-title":"Nat. Commun."},{"key":"B105","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.stem.2019.04.001","article-title":"Highly efficient and marker-free genome editing of human pluripotent stem cells by CRISPR-Cas9 RNP and AAV6 donor-mediated homologous recombination","volume":"24","author":"Martin","year":"2019","journal-title":"Cell Stem Cell"},{"key":"B106","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1038\/S41467-024-48092-9","article-title":"In vivo genome editing via CRISPR\/Cas9-Mediated homology-independent targeted integration for bietti crystalline corneoretinal dystrophy treatment","volume":"15","author":"Meng","year":"2024","journal-title":"Nat. Commun."},{"key":"B107","doi-asserted-by":"publisher","first-page":"4728","DOI":"10.1182\/BLOOD-2005-09-3605","article-title":"Phenotypic Correction of von Willebrand Disease Type 3 Blood-Derived Endothelial Cells with Lentiviral Vectors Expressing von Willebrand Factor","volume":"107","author":"Meyer","year":"2006","journal-title":"Blood"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1161\/ATVBAHA.108.168369","article-title":"Restoration of Plasma von Willebrand Factor Deficiency Is Sufficient to Correct Thrombus Formation after Gene Therapy for Severe von Willebrand Disease","volume":"28","author":"Meyer","year":"2008","journal-title":"Arteriosclerosis, Thrombosis, Vasc. Biol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/S44321-024-00072-8","article-title":"GP64-Pseudotyped lentiviral vectors target liver endothelial cells and correct hemophilia A mice","volume":"16","author":"Milani","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/MT.2015.218","article-title":"Streptococcus thermophilus CRISPR-Cas9 systems enable specific editing of the human genome","volume":"24","author":"M\u00fcller","year":"2016","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B111","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41434-024-00499-1","article-title":"Prime editing: therapeutic advances and mechanistic insights","volume":"32","author":"Murray","year":"2025","journal-title":"Gene Ther."},{"key":"B112","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/J.MOLCEL.2021.12.026","article-title":"CRISPR-based genome editing through the lens of DNA repair","volume":"82","author":"Nambiar","year":"2022","journal-title":"Mol. Cell"},{"key":"B113","unstructured":"ClinVar\n          \n          \n          2025"},{"key":"B114","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/S41587-021-01039-7","article-title":"Engineered PegRNAs improve prime editing efficiency","volume":"40","author":"Nelson","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41587-019-0325-6","article-title":"Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency","volume":"38","author":"Nguyen","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/J.1365-2516.2007.01643.X","article-title":"Von Willebrand Disease (VWD): evidence-based Diagnosis and Management Guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel Report (USA)","volume":"14","author":"Nichols","year":"2008","journal-title":"Haemoph. Official J. World Fed. Hemophilia"},{"key":"B117","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/S12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J. Nanobiotechnology"},{"key":"B118","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/J.OMTM.2021.10.015","article-title":"Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device","volume":"23","author":"Olgasi","year":"2021","journal-title":"Mol. Ther. - Methods and Clin. Dev."},{"key":"B119","unstructured":"Von Willebrand disease type 1"},{"key":"B120","unstructured":"Von Willebrand disease type 2"},{"key":"B121","doi-asserted-by":"publisher","first-page":"e12635","DOI":"10.1002\/RTH2.12635","article-title":"2B von Willebrand Disease Diagnosis: considerations Reflecting on 2021 Multisociety Guidelines","volume":"5","author":"Othman","year":"2021","journal-title":"Res. Pract. Thrombosis Haemostasis"},{"key":"B190","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-27183-x","article-title":"Find and cut-and-transfer (FiCAT) Mammalian genome engineering","volume":"12","author":"Pallar\u00e8s-Masmitj\u00e0","year":"2021","journal-title":"Nat. Commun."},{"key":"B123","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/S41551-024-01227-1","article-title":"Efficient site-specific integration of large genes in Mammalian cells via continuously evolved recombinases and prime editing","volume":"9","author":"Pandey","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"B124","doi-asserted-by":"publisher","first-page":"e2201095","DOI":"10.1002\/ADMA.202201095","article-title":"Anionic lipid nanoparticles preferentially deliver MRNA to the hepatic reticuloendothelial system","volume":"34","author":"Pattipeiluhu","year":"2022","journal-title":"Adv. Mater. Deerf. Beach, Fla."},{"key":"B125","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/01.BRS.0000058946.64222.92","article-title":"Potential use of Sox9 gene therapy for intervertebral degenerative disc disease","volume":"28","author":"Paul","year":"2003","journal-title":"Spine"},{"key":"B126","doi-asserted-by":"publisher","first-page":"115274","DOI":"10.1016\/J.ADDR.2024.115274","article-title":"Translating ultrasound-mediated drug delivery technologies for CNS applications","volume":"208","author":"Perolina","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B127","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.3390\/CANCERS12113354","article-title":"Oncolytic adenovirus in cancer immunotherapy","volume":"12","author":"Peter","year":"2020","journal-title":"Cancers"},{"key":"B128","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/J.TRANSCI.2019.08.009","article-title":"A personalized approach to the management of VWD","volume":"58","author":"Phua","year":"2019","journal-title":"Transfus. Apher. Sci."},{"key":"B129","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1182\/BLOOD-2016-04-713289","article-title":"Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A","volume":"128","author":"Pipe","year":"2016","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/JTH.13938","article-title":"High and Long\u2010term von Willebrand Factor Expression after Sleeping Beauty Transposon\u2010mediated Gene Therapy in a Mouse Model of Severe von Willebrand Disease","volume":"16","author":"Portier","year":"2018","journal-title":"J. Thrombosis Haemostasis"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-49943-1","article-title":"ABE-ultramax for high-efficiency biallelic adenine base editing in zebrafish","volume":"15","author":"Qin","year":"2024","journal-title":"Nat. Commun."},{"key":"B132","doi-asserted-by":"publisher","first-page":"699","DOI":"10.18632\/ONCOTARGET.28651","article-title":"Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition","volume":"15","author":"Rackear","year":"2024","journal-title":"Oncotarget"},{"key":"B133","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/NATURE14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"B134","doi-asserted-by":"publisher","first-page":"9985","DOI":"10.1074\/jbc.M006548200","article-title":"Identification of the Collagen-Binding Site of the von Willebrand Factor A3-Domain","volume":"276","author":"Romijn","year":"2001","journal-title":"J. Biol. Chem."},{"key":"B135","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/HAE.14547","article-title":"Von Willebrand Disease and von Willebrand Factor","volume":"28","author":"Sadler","year":"2022","journal-title":"Haemoph. Official J. World Fed. Hemophilia"},{"key":"B136","doi-asserted-by":"publisher","first-page":"E9944","DOI":"10.1073\/pnas.1811276115","article-title":"High-throughput in vivo screen of functional MRNA delivery identifies nanoparticles for endothelial cell gene editing","volume":"115","author":"Sago","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B137","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s41587-020-0509-0","article-title":"Base editors for simultaneous introduction of C-to-T and A-to-G mutations","volume":"38","author":"Sakata","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/J.JCONREL.2017.09.044","article-title":"Highly specific delivery of SiRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus","volume":"266","author":"Sato","year":"2017","journal-title":"J. Control. Release"},{"key":"B139","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/RTH2.12242","article-title":"Alternative Trafficking of Weibel\u2010Palade Body Proteins in CRISPR\/Cas9\u2010engineered von Willebrand Factor\u2013Deficient Blood Outgrowth Endothelial Cells","volume":"3","author":"Schillemans","year":"2019","journal-title":"Res. Pract. Thrombosis Haemostasis"},{"key":"B140","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/CPT.1639","article-title":"Regulators\u2019 advice can make a difference: european medicines agency approval of zynteglo for beta thalassemia","volume":"107","author":"Schuessler-Lenz","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B141","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41525-023-00375-8","article-title":"Population-Based Prevalence and Mutational Landscape of von Willebrand Disease Using Large-Scale Genetic Databases","volume":"8","author":"Seidizadeh","year":"2023","journal-title":"Npj Genomic Med."},{"key":"B142","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/S41587-023-01888-4","article-title":"High-efficiency transgene integration by homology-directed repair in human primary cells using DNA-PKcs inhibition","volume":"42","author":"Selvaraj","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1186\/s12967-022-03729-5","article-title":"Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-Cell products","volume":"20","author":"Shao","year":"2022","journal-title":"J. Transl. Med."},{"key":"B144","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nsmb.3344","article-title":"Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B","volume":"24","author":"Shi","year":"2016","journal-title":"Nat. Struct. and Mol. Biol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/415331a","article-title":"Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity","volume":"415","author":"Shiver","year":"2002","journal-title":"Nat. 2002"},{"key":"B146","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1182\/blood-2015-10-677054","article-title":"Von Willebrand Factor Multimerization and the Polarity of Secretory Pathways in Endothelial Cells","volume":"128","author":"Silva","year":"2016","journal-title":"Blood"},{"key":"B147","doi-asserted-by":"publisher","first-page":"205ra134","DOI":"10.1126\/SCITRANSLMED.3006843","article-title":"A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity","volume":"5","author":"Smaill","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"B148","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/HAE.14263","article-title":"Occurrence Rates of von Willebrand Disease among People Receiving Care in Specialized Treatment Centres in the United States","volume":"27","author":"Soucie","year":"2021","journal-title":"Haemoph."},{"key":"B149","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0065-2660(10)69015-3","article-title":"Strategies for targeting tumors and tumor vasculature for cancer therapy","volume":"69","author":"Sreeramoju","year":"2010","journal-title":"Adv. Genet."},{"key":"B150","doi-asserted-by":"publisher","first-page":"LBA-3","DOI":"10.1182\/BLOOD-2021-155018","article-title":"Fitusiran, an investigational SiRNA therapeutic targeting antithrombin for the treatment of hemophilia: first results from a phase 3 study to evaluate efficacy and safety in people with hemophilia a or B without inhibitors (ATLAS-A\/B)","volume":"138","author":"Srivastava","year":"2021","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/HAE.14810","article-title":"Reported Prevalence of von Willebrand Disease Worldwide in Relation to Income Classification","volume":"29","author":"Stonebraker","year":"2023","journal-title":"Haemophilia"},{"key":"B152","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1126\/SCIENCE.AAX9181","article-title":"RNA-guided DNA insertion with CRISPR-associated transposases","volume":"365","author":"Strecker","year":"2019","journal-title":"Sci. (New York, N.Y.)"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/J.1365-2516.2009.02059.X","article-title":"The Mutation Spectrum Associated with Type 3 von Willebrand Disease in a Cohort of Patients from the North West of England","volume":"15","author":"Sutherland","year":"2009","journal-title":"Haemophilia"},{"key":"B154","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/MT.2013.188","article-title":"Integration-Deficient lentiviral vectors expressing codon-optimized R338L human FIX restore normal hemostasis in hemophilia B mice","volume":"22","author":"Suwanmanee","year":"2014","journal-title":"Mol. Ther."},{"key":"B155","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nature20565","article-title":"In vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration","volume":"540","author":"Suzuki","year":"2016","journal-title":"Nature"},{"key":"B156","doi-asserted-by":"publisher","first-page":"790121","DOI":"10.3389\/fmicb.2021.790121","article-title":"Virus-Like particles: revolutionary platforms for developing vaccines against emerging infectious diseases","volume":"12","author":"Tariq","year":"2022","journal-title":"Front. Microbiol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41587-022-01595-6","article-title":"Programmable A-to-Y base editing by fusing an adenine base editor with an N-Methylpurine DNA glycosylase","volume":"41","author":"Tong","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.1038\/s41467-024-49343-5","article-title":"Development of deaminase-free T-to-S base editor and C-to-G base editor by engineered human uracil DNA glycosylase","volume":"15","author":"Tong","year":"2024","journal-title":"Nat. Commun."},{"key":"B159","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1111\/JTH.14886","article-title":"Bleeding Symptoms in Patients Diagnosed as Type 3 von Willebrand Disease: results from 3WINTERS\u2010IPS, an International and Collaborative Cross\u2010sectional Study","volume":"18","author":"Tosetto","year":"2020","journal-title":"J. Thrombosis Haemostasis"},{"key":"B160","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1089\/CRISPR.2023.0005","article-title":"Efficient genome and base editing in human cells using ThermoCas9","volume":"6","author":"Trasanidou","year":"2023","journal-title":"CRISPR J."},{"key":"B161","unstructured":"UCSC genome browser home\n          \n          \n          2025"},{"key":"B162","doi-asserted-by":"publisher","first-page":"102599","DOI":"10.1016\/J.RPTH.2024.102599","article-title":"Prophylaxis in von Willebrand Disease with von Willebrand Factor Concentrate and Nonfactor Therapies","volume":"8","author":"van Kwawegen","year":"2024","journal-title":"Res. Pract. Thrombosis Haemostasis"},{"key":"B163","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1055\/S-0042-1757635","article-title":"Analysis of von Willebrand Disease in the \u2018Heart of Europe","volume":"6","author":"Vangenechten","year":"2022","journal-title":"TH Open Companion J. Thrombosis Haemostasis"},{"key":"B164","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/gt.2011.143","article-title":"Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors","volume":"19","author":"Varadi","year":"2011","journal-title":"Gene Ther."},{"key":"B165","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41580-023-00697-6","article-title":"CRISPR technologies for genome, epigenome and transcriptome editing","volume":"25","author":"Villiger","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.3390\/V15091801","article-title":"Innate immune response to viral vectors in gene therapy","volume":"15","author":"Wang","year":"2023","journal-title":"Viruses"},{"key":"B167","doi-asserted-by":"publisher","first-page":"108515","DOI":"10.1016\/J.MRREV.2024.108515","article-title":"Advances in base editing: a focus on base transversions","volume":"794","author":"Wang","year":"2024","journal-title":"Mutat. Res. - Rev. Mutat. Res."},{"key":"B168","doi-asserted-by":"publisher","first-page":"eabo6405","DOI":"10.1126\/sciadv.abo6405","article-title":"A highly specific CRISPR-Cas12j nuclease enables allele-specific genome editing","volume":"9","author":"Wang","year":"2023","journal-title":"Sci. Adv."},{"key":"B169","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3390\/VACCINES12101148","article-title":"Recent advances in lipid nanoparticles and their safety concerns for MRNA delivery","volume":"12","author":"Wang","year":"2024","journal-title":"Vaccines"},{"key":"B170","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/MT.2009.122","article-title":"Integration-Deficient lentiviral vectors: a slow coming of age","volume":"17","author":"Wanisch","year":"2009","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/J.HOC.2021.07.004","article-title":"Von Willebrand Disease: current Status of Diagnosis and Management","volume":"35","author":"Weyand","year":"2021","journal-title":"Hematology\/Oncology Clin. N. Am."},{"key":"B172","doi-asserted-by":"publisher","first-page":"eadt5199","DOI":"10.1126\/SCIENCE.ADT5199","article-title":"Programmable gene insertion in human cells with a laboratory-evolved CRISPR-associated transposase","volume":"388","author":"Witte","year":"2025","journal-title":"Science"},{"key":"B173","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"B174","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1016\/J.MOLCEL.2022.11.003","article-title":"The miniature CRISPR-Cas12m effector binds DNA to block transcription","volume":"82","author":"Wu","year":"2022","journal-title":"Mol. Cell"},{"key":"B175","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/s41589-023-01380-9","article-title":"An engineered hypercompact CRISPR-Cas12f system with boosted gene-editing activity","volume":"19","author":"Wu","year":"2023","journal-title":"Nat. Chem. Biol."},{"key":"B176","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.1038\/s41467-023-40655-6","article-title":"AAV-mediated base-editing therapy ameliorates the disease phenotypes in a mouse model of retinitis pigmentosa","volume":"14","author":"Wu","year":"2023","journal-title":"Nat. Commun."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1364135","DOI":"10.3389\/fphar.2024.1364135","article-title":"Breaking genetic shackles: the advance of base editing in genetic disorder treatment","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1186\/S12967-024-05957-3","article-title":"From bench to bedside: cutting-edge applications of base editing and prime editing in precision medicine","volume":"22","author":"Xu","year":"2024","journal-title":"J. Transl. Med."},{"key":"B179","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1182\/BLOOD.V92.8.2791","article-title":"Tissue Distribution and Regulation of Murine von Willebrand Factor Gene Expression in vivo","volume":"92","author":"Yamamoto","year":"1998","journal-title":"Blood"},{"key":"B180","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41586-024-07259-6","article-title":"Improving prime editing with an endogenous small RNA-binding protein","volume":"628","author":"Yan","year":"2024","journal-title":"Nature"},{"key":"B181","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41587-022-01527-4","article-title":"Drag-and-Drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases","volume":"41","author":"Yarnall","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"B182","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1161\/CIRCULATIONAHA.118.035889","article-title":"BOLA (bolA family member 3) deficiency controls endothelial metabolism and Glycine homeostasis in pulmonary hypertension","volume":"139","author":"Yu","year":"2019","journal-title":"Circulation"},{"key":"B183","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1038\/s41467-021-25448-z","article-title":"Efficient intracellular delivery of proteins by a multifunctional chimaeric peptide in vitro and in vivo","volume":"12","author":"Yu","year":"2021","journal-title":"Nat. Commun."},{"key":"B184","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/J.CELL.2015.09.038","article-title":"Cpf1 is a single RNA-Guided endonuclease of a class 2 CRISPR-cas system","volume":"163","author":"Zetsche","year":"2015","journal-title":"Cell"},{"key":"B185","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1126\/science.1170905","article-title":"Mechanoenzymatic Cleavage of the Ultralarge Vascular Protein von Willebrand Factor","volume":"324","author":"Zhang","year":"2009","journal-title":"Science"},{"key":"B186","doi-asserted-by":"publisher","first-page":"110196","DOI":"10.1016\/J.CELREP.2021.110196","article-title":"Robust genome editing in adult vascular endothelium by nanoparticle delivery of CRISPR-Cas9 plasmid DNA","volume":"38","author":"Zhang","year":"2022","journal-title":"Cell Rep."},{"key":"B187","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3390\/V17020239","article-title":"Adeno-associated virus vectors: principles, practices, and prospects in gene therapy","volume":"17","author":"Zwi-Dantsis","year":"2025","journal-title":"Viruses"}],"updated-by":[{"DOI":"10.3389\/fgeed.2025.1719330","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000}}],"container-title":["Frontiers in Genome Editing"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgeed.2025.1620438\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:50:18Z","timestamp":1762505418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgeed.2025.1620438\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":190,"alternative-id":["10.3389\/fgeed.2025.1620438"],"URL":"https:\/\/doi.org\/10.3389\/fgeed.2025.1620438","relation":{},"ISSN":["2673-3439"],"issn-type":[{"value":"2673-3439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"article-number":"1620438"}}